(Q37982433)

26 August 2017

title

Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer (English)

1 reference

26 August 2017

main subject

metastatic breast cancer

1 reference

1

Gillian M Keating

1 reference

26 August 2017

publication date

1 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

72

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

353-360

1 reference

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Role of HER2 gene overexpression in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

HER2 therapy--an abundance of riches.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209000-000000000-00000

Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.

21 January 2018

1 reference

12 December 2020

Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.

1 reference

12 December 2020

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

12 December 2020

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

1 reference

12 December 2020

10.2165/11209000-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1027541017

0 references

1 reference